Bionorica AG successful in the market for plant-based medicines
The German market leader - Bionorica Group - for pharmacy-only plant-based medicines (phytopharmaceuticals) has further extended its market share in Germany. The company markets a total of 14 phytopharmaceuticals in the areas of airways, the immune system, gynaecology and urology and is researching intensively for innovative solutions in a variety of fields of disease. The corresponding licensing procedures for further preparations are anticipated from 2009. The worldwide company with leading scientists, clinics, universities and research institutes wants to become even more global and is concentrating now on the pharmaceutical markets in the USA, China, Japan, India and Brasil. Currently the medicines produced by the company are already marketed in more than 50 countries worldwide. The German market leader sees above all in the short term achievable potential in the USA: Here the number of serious side effects from medicines has risen threefold in eight years. Above all to protect children, the American licencing authority FDA issued a warning at the end of last year regarding synthetic chemical based medicines for use in children under six years of age. For expected growth in 2008 and in following years, the company anticipates the increase in total of 14.5% in the number of employees in 2007 (749 employees) to be once again significantly increased upon.
For more information see: